In vitro degradation and antitumor activity of oxime bond-linked daunorubicin–GnRH-III bioconjugates and DNA-binding properties of daunorubicin–amino acid metabolites
作者:Erika Orbán、Gábor Mező、Pascal Schlage、Gabriella Csík、Žarko Kulić、Philipp Ansorge、Erzsébet Fellinger、Heiko Michael Möller、Marilena Manea
DOI:10.1007/s00726-010-0766-1
日期:2011.7
results show that (1) all synthesized bioconjugates have in vitro antitumor effect, (2) they are stable in human serum at least for 24 h, except for the compound containing an YRRL spacer and (3) they are hydrolyzed by cathepsin B and in the lysosomal homogenate. To investigate the relationship between the in vitro antitumor activity and the structure of the bioconjugates, the smallest metabolites produced
具有受体介导的肿瘤靶向功能并带有细胞毒性剂的生物结合物应能将化学治疗药物特异性地递送至恶性组织,从而在限制外周毒性的同时提高其局部疗效。在本研究中,促性腺激素释放激素III(GnRH-III; Glp-His-Trp-Ser-His-Asp-Trp-Lys-Pro-Gly-NH 2)被用作靶向部分,柔红霉素通过肟键直接或通过插入GFLG或YRRL四肽间隔基连接到柔红霉素上。通过3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四唑溴化物测定法测定了生物缀合物在MCF-7人乳腺癌和HT-29人结肠癌细胞上的体外抗肿瘤活性。通过液相色谱结合质谱法分析了它们的降解/稳定性(1)在人血清中,(2)在组织蛋白酶B存在下和(3)在大鼠肝溶酶体匀浆中。结果表明:(1)所有合成的生物缀合物均具有体外抗肿瘤作用;(2)除含有YRRL间隔基的化合物外,它们在人血清中至少稳定24 h;(3)它们被组织蛋白酶B水